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Abstract 
HOX transcription factors play an important role in determining body patterning and cell fate 
during embryogenesis. Accumulating evidence has shown that these genes act as positive and/or 
negative modulators in many types of cancer, including breast cancer, in a tissue-specific manner. 
We have previously reported that HOXB5 is aberrantly overexpressed in breast cancer tissues 
and cell lines. Here, we investigated the biological roles and clinical relevance of HOXB5 in breast 
cancer. Immunohistochemical analysis of HOXB5 on tissue microarray (TMA) including 34 normal 
and 67 breast cancer specimens revealed that HOXB5 was highly expressed in cancer tissues, 
particularly from estrogen receptor (ER)-positive breast cancer patients. An online survival 
analysis confirmed the correlation between HOXB5 expression and poor distant metastasis-free 
survival in ER-positive, but not in ER-negative, breast cancer. In vitro studies indicated that HOXB5 
silencing in ER-positive cells significantly decreased cell proliferation and anchorage-independent 
cell growth. In contrast, overexpression of HOXB5 displayed EMT characteristics with a greater 
invasive ability, higher cell proliferation and colony formation in soft agar. HOXB5 knockdown or 
overexpression led to changes in the expression levels of RET, ERBB2, and EGFR, but not of ESR1. 
In conclusion, we suggest that HOXB5 acts as a positive modulator most likely by promoting cell 
proliferative response and invasiveness in ER-positive breast cancer. These results would help 
predict prognosis of breast cancer and identify a new valuable therapeutic target. 
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Introduction 
HOX genes are a subset of homeobox genes and 
encode transcriptional factors which play important 
roles in cell proliferation, differentiation, and the de-
termination of cell identity [1]. In addition, many 
HOX genes have been shown to be associated with 
cancer [2, 3]. In particular, several studies have shown 
the prognostic value of specific HOX genes, such as 
HOXA5, HOXA9, HOXB7, and HOXB13, as well as 
the molecular mechanisms underlying the regulation 
of gene expression and cell growth in breast cancer 
[4-9]. Although recent progress in this area has re-
vealed potential targets that could increase the effec-
tiveness of breast cancer treatments, there is still a 
demand to discover new oncogenes and possible 
treatment targets for specific types of breast cancer.  
In our previous study, we have proposed 14 
HOX genes, HOXA6, -A13, -B2, -B4, -B5, -B6, -B7, -B8, 
-B9, -C5, -C9, -C13, -D1, and -D8, as putative candi-
dates associated with the development and progres-









significantly different expression pattern between 
non-malignant and malignant breast tissues as well as 
breast cancer cell lines [10]. Several HOX genes, such 
as HOXB7 and -B9, have already been reported to act 
as positive modulators in breast cancer [8, 11]. How-
ever, the other genes have not been investigated for 
their clinical and biological roles in breast cancer.  
HOXB5 is known to play an important role in the 
development of the enteric nervous system (ENS) 
[12]. Abnormalities in HOXB5 function lead to 
Hirschsprung’s disease via downregulation of the 
receptor tyrosine kinase RET (REarranged during 
Transfection) [12]. A recent study demonstrated that 
HOXB5 directly binds to the promoter of the RET 
gene and enhanced RET expression in a neuroblas-
toma cell line [13]. Interestingly, RET has been known 
to behave as an oncogene in several cancers including 
breast cancer [14]. In addition, HOXB5-regulated 
vascular endothelial growth factor receptor 2 
(VEGFR2), angiopoietin 2 (ANG2), and alpha 2 integ-
rin (ITGa2) have also been shown to play roles in 
breast cancer biology [15-20]. Therefore, we consid-
ered HOXB5 to be one of the most promising candi-
date associated with the development and progres-
sion of breast cancer. 
To evaluate the clinical significance of HOXB5 in 
breast cancer and demonstrate an association between 
breast cancer progression and HOXB5 expression, we 
analyzed the expression of HOXB5 in patients with 
invasive breast cancer and performed in vitro studies. 
Our results showed that HOXB5 was highly ex-
pressed in some breast cancers, especially in estrogen 
receptor (ER)-positive tumors. In breast cancer cell 
lines, HOXB5 induced the epithelial-mesenchymal 
transition (EMT) and promoted tumor cell prolifera-
tion and growth as well as invasion. 
Materials and methods 
Cell culture, plasmids, and cell line construc-
tion 
MCF7, T47D, MCF10A, and MDA-MB-231 cells 
were kindly provided by Drs. Yong Nyun Kim and 
Kyung tae Kim (National Cancer Center, Korea). 
MCF7 and MDA-MB-231 cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM; WelGENE 
Inc., Deagu, Korea) supplemented with 10% fetal bo-
vine serum (FBS, WelGENE Inc.) and 1x antibiotic 
antimycotic solution (WelGENE Inc.). T47D cells were 
grown in RPMI 1640 (WelGENE Inc.) with the same 
supplementation. MCF10A was cultured in 
DMEM/F12 (WelGENE Inc.) supplemented with 5% 
horse serum, 20 ng/ml epidermal growth factor 
(EGF), 0.5 μg/ml hydrocortisone, 100 ng/ml cholera 
toxin, 10 μg/ml insulin, and 100 μg/ml penicil-
lin-streptomycin. A set of pLKO.1 lentiviral vectors 
containing seven different shRNA targeting HOXB5 
was purchased from Thermo Fisher Scientific (Rock-
ford, IL USA). For the control, pLKO.1 lentiviral vec-
tor harboring nonspecific shRNA (shNS-puro) were 
used. Lentiviral particles were produced in 293T cells 
by co-transfection with lentiviral packaging and en-
velop plasmids (pCMV Δ8.91 and pMD 1G), which 
were kindly provided by Dr. Seok Hyung Kim (De-
partment of pathology, Samsung Medical Center, 
Seoul, Korea). The T47D cells were transduced with 
lentiviral particles. Through antibiotic selection using 
puromycin at a concentration of 0.5 μg/ml, stable cell 
lines were obtained and the protein levels were con-
firmed using Western blotting analysis. For the over-
expression studies, a full-length cDNA of the HOXB5 
gene was cloned into the EcoRI-XbaI site of the 
pcDNA3-HA-tagged expression vector. To establish 
stable cell lines, G418 was treated for 2~3 weeks with 
a concentration of 300 μg/ml.  
Total RNA Isolation and RT-PCR  
Total RNA was isolated from the cultured cells 
using Trizol reagent (Invitrogen, Carlsbad, CA, USA). 
Reverse transcription was conducted with 1 μg of 
total RNA using ImProm-ll TM Reverse Transcriptase 
(Promega, Madison, WI, USA). PCR was performed 
using Taq polymerase (Bioneer, Seongnam, Korea). 
For the quantitative PCR, SYBR Green PCR Master 
Mix (Applied Biosystems, Calrlsbad, CA, USA) was 
used and then subjected to real time PCR quantifica-
tion using the ABI7300 (Applied Biosystems). All re-
actions were done in triplicate, and the relative 
amounts of all mRNAs were calculated by using the 
comparative CT method. β-actin mRNA was used as 
the invariant control. All primer sequences were pro-
vided in Supplementary Table S1. 
Western blot, immunocytochemistry, and an-
tibodies 
Cells were lysed in Nondet P-40 (NP-40) lysis 
buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1% 
NP-40, and Protease Inhibitor Cocktail). Protein con-
centrations were estimated by the BCA Protein Assay 
Kit (Thermo). After the immune blotting, the signals 
were detected using SuperSignal West Pico Chemi-
luminescent Substrate (Pierce, Rockford, IL USA). The 
primary antibodies used were rabbit anti-HOXB5 
(Abcam, Cambridge, MA, USA), rabbit an-
ti-E-cadherin (Abcam), anti-β-catenin (BD, San Jose, 
CA, USA), anti-HA tag (Abcam), and anti- β-actin 
(Sigma, St. Louis, MO, USA). For the immunocyto-
chemistry, the cells were fixed with 4% PFA and in-
cubated in the blocking buffer (0.1% Triton X-100 
containing 1% goat serum) for 30 min. Antibodies to 





HOXB5 (Abcam), E-cadherin (Abcam), Vimentin 
(Abcam), and β-catenin (BD) were used. 
MTT assay 
Cells were trypsinized, counted, and plated in 
96-well plates at a density of 7.5x103 cells per well. On 
designated days, the cells were stained with 20 μl of 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide, Sigma) for 3.5 hours at 37°C, fol-
lowed by removal of the culture medium and incuba-
tion with 100 μl of MTT solvent (4 mM HCl, 0.1% 
NP40 in isopropanol). The absorbance was measured 
with an ELISA reader (Softmax Pro) at 560 nm. All 
experiments were performed in triplicate. The tamox-
ifen sensitivity was measured by MTT assay with the 
treatment of 4-hydroxytamoxifen (Sigma).  
Soft agar colony-forming assay 
Sterile agarose solution (1% and 0.7% agarose in 
sterile water) were mixed with the same volume of 2× 
RPMI with 20% FBS and used as bottom and top lay-
ers, respectively. The cells were adjusted to a volume 
of 5x103 cells in 100 μl of appropriate culture medium 
with serum, and then were added to the bottom layer. 
The plates were incubated at 37°C in a humidified 
incubator for 14 to 21 days. The cells were fed twice a 
week by adding 0.5 ml of fresh culture medium. 
Colonies were stained with 0.5 ml of NBT (0.5 mg/ml 
in PBS) and photographed with a digital camera 
(Kodak). The acquired images were analyzed using 
the ImageJ software.  
Matrigel invasion assay 
Matrigel™ (BD) was mixed with coating buffer 
(0.01 M Tris, pH 8.0 and 0.7% NaCl) to a final con-
centration 200-300 μg/ml. Individual inserts were 
coated with 100 μl of coating solution in a 24-well 
plate. Then, 5 × 104 cells were added to the top of this 
Matrigel™ layer. The culture medium with 10% FBS 
was added to the lower chamber as a chemoattractant. 
The cells were incubated at 37°C for 24-72 hours. The 
cells that had invaded through the Matrigel™ and 
reached the lower surface of the filter were stained 
with fluorochrome 4',6-diamidino-2-phenylindole 
(DAPI) and observed by fluorescent microscopy. The 
acquired images were analyzed using the ImageJ 
software.  
Tissue microarray and immunohistochemistry 
(TMA-IHC) 
Among patients who had undergone surgical 
resection for breast cancer between January 2000 and 
December 2004 at National Health Insurance Service 
Ilsan Hospital, Gyeonggi-do, Korea, 67patients were 
selected because their paraffin blocks had been well 
preserved and tumor in a single tissue block was suf-
ficient for the construction of TMA. Data regarding 
patient demographics and the histopathology of the 
primary tumor were retrospectively obtained by re-
viewing medical records. In this particular case, no 
consent from patients was needed according to the 
South Korea’s Bioethics and Safety Act. The Ethics 
Committee for the Clinical Research of the Institu-
tional Review Board of the National Health Insurance 
Service Ilsan Hospital, Gyeonggi-do, Korea, approved 
this study protocol (SU-YON 2013-129). Forma-
lin-fixed, paraffin-embedded tissue blocks were ar-
rayed using a tissue-arraying instrument (Ac-
cuMax_Array; Petagen Inc., Seoul, Korea). Briefly, 
representative areas of each tumor were selected and 
marked on the H&E slide by breast pathologists. In 34 
cases, normal tissues adjacent to each tumor were also 
circled for scoring. The designated zone of each donor 
block was punched with a tissue cylinder 2 mm in 
diameter and the sample was transferred to a recipi-
ent block in a grid pattern. Immunohistochemical 
staining was carried out in the tissue microarray 
blocks. Thick sections of 4 μm were obtained with a 
microtome, transferred into adhesive slides, and dried 
at 59°C for an hour. After deparaffinization and re-
hydration, the sections were treated with a 3% hy-
drogen peroxide solution for 10 min to block endog-
enous peroxidase and then pretreated for antigen re-
trieval in 10 mM citrate buffer (pH 6.0) in a micro-
wave oven for 20 min. After incubation with primary 
antibodies against HOXB5 (Abcam), immunodetec-
tion was carried out with biotinylated anti-mouse 
immunoglobulin antibody (DAKO, Kyoto, Japan), 
followed by peroxidase-labeled streptavidin using a 
labeled streptavidin biotin kit with 
3,3’-diaminobenzidine chromogen as the substrate. 
Slides were counterstained with Harris hematoxylin. 
Brown nuclear or cytoplasmic staining for HOXB5 
was considered positive. For semi-quantitative analy-
sis, HOXB5 immunostaining signals were scored us-
ing the Allred scoring system. The proportion score 
was rated as 0 = no cells stained positive, 1 = less than 
1/100 positive, 2 = between 1/100 and 1/10, 3 = be-
tween 1/10 and 1/3, 4 = between 1/3 and 2/3, and 5 = 
more than 2/3. The intensity score was made on the 
basis of the average intensity of staining: 0 = negative, 
1 = weak, 2 = moderate and 3 = strong (Fig. 1). The 
final score was the sum of the intensity score and the 
proportion score. A final staining score ≥ 3 was con-
sidered to be positive. For the Kaplan-Meier analysis, 
an online database [21] was used with gene expres-
sion data and survival information on 4,142 patients 
downloaded from the NCBI Gene Expression Omni-
bus (GEO; Affymetrix Microarrays only), the Euro-
pean Genome-phenome Archive (EGA), and the 
Cancer Genome Atlas (TCGA).  






Figure 1. Immunohistochemical staining for HOXB5. The HOXB5 expression levels were categorized as negative (A), weak (B), moderate (C), and strong positive 




The clinicopathologic variables were compared 
by the Chi-square test or Fisher’s exact test. The in-
dependent t-test was used for comparison of age. 
Distant metastasis-free survival (DMFS) time was 
measured from the date of operation to the date of the 
first distant metastasis. Survival curves based on the 
Kaplan–Meier method were compared using a 
log-rank test. All statistical tests were two-sided and 
p-values of less than 0.05 were considered statistically 
significant. SPSS for Windows version 21.0 (SPSS Inc., 
Chicago, IL, USA) was used for statistical analyses. 
Results from the in vitro assay are expressed as mean ± 
SEM and were analyzed using the paired t-test. Dif-
ferences were considered significant at p < 0.05.  
Results 
Clinical significance of HOXB5 in breast can-
cer 
To assess whether there is a difference in HOXB5 
protein expression between normal breast tissues and 
breast cancer tissues, 34 breast cancer tissues and 
paired 34 normal breast tissues which were obtained 
from the same specimens were analyzed by 
TMA-IHC. Among 34 pairs, 41.2% of breast cancer 
tissues and 29.4% of normal breast tissues were 
HOXB5 positive (Table 1). Especially, among 17 pairs 
which were ER positive cases, HOXB5 protein ex-
pression was significantly higher in breast cancer tis-
sues than in normal breast tissues (64.7% in cancers 
and 11.8% in normal tissues, p = 0.001; Table 1). When 
correlation analysis was performed between the ex-
pression of HOXB5 and various clinicopathological 
features, ER-positive patients had higher HOXB5 ex-
pression (p < 0.001; Table 2). Other clinical character-
istics such as tumor size, lymphatic metastasis, tumor 
stage, and histologic grade were not positively related 




Table 1. Analysis of HOXB5 expression in breast specimens 
 HOXB5 positiv-
ity 
Normal Cancer p-value 
All cases negative 24 (70.6%) 20 (58.8%) 0.310 
 positive 10 (29.4%) 14 (41.2%)  
ER positive cases negative 15 (88.2%) 6 (35.3%) 0.001 
 positive 2 (11.8%) 11 (64.7%)  
ER, estrogen receptor 
 





Table 2. Correlation analysis between HOXB5 expression and 
various clinicopathological features 





Age 48.0 ± 12.5 50.2 ± 12.3 0.468 
Tumor size    
≤ 2 cm 14 (40.0%) 15 (46.9%) 0.570 
> 2 cm 21 (60.0%) 17 (53.1%)  
Node status    
No metastasis 17 (48.6%) 16 (50.0%) 0.907 
Metastasis 18 (51.4%) 16 (50.0%)  
Stage    
I, II 25 (71.4%) 25 (78.1%) 0.529 
III, IV 10 (28.6%) 7 (21.9%)  
Histologic grade    
I 6 (18.8%) 10 (32.3%) 0.218 
II, III 26 (81.2%) 21 (67.7%)  
ER status    
Negative 23 (65.7%) 5 (15.6%) < 0.001 
Positive 12 (34.3%) 27 (84.4%)  
PR status    
Negative 9 (25.7%) 5 (15.6%) 0.310 
Positive 26 (74.3%) 27 (84.4%)  
HER2 status    
Negative 26 (74.3%) 26 (81.3%) 0.495 
Positive 9 (25.7%) 6 (18.8%)  
HOXB5 positive was defined by Allred score ≥3. 
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth 
factor receptor 2. 
 
To assess the survival of breast cancer patients in 
the context of HOXB5 expression levels, DMFS curves 
were drawn and compared using the Kaplan-Meier 
method and the log-rank test, respectively. However, 
we found no significant difference between the 
HOXB5-positive and HOXB5-negative groups in 
terms of DMFS (data not shown). The reliability of the 
subgroup analysis was poor due to the limited num-
ber of cases in this set. Therefore, we further analyzed 
a publicly available database [21] and confirmed that 
HOXB5 had no impact on DMFS when all patients 
were analyzed together without bias, which was con-
sistent with the result based on our sample set (Fig. 
2A). However, a higher expression of HOXB5 was 
related to poor DMFS when only the ER-positive 
breast cancer patients were analyzed (p = 0.037; Fig. 
2B). The higher expression of HOXB5 was also linked 
to poor DMFS for patients with ER-positive, lymph 
node-negative, and histologic grade (HG) I breast 
cancer (p = 0.036), who usually had good prognosis 
and were occasionally treated with endocrine therapy 
alone (Fig. 2C). Furthermore, a higher expression of 
HOXB5 was associated with poor endocrine respon-
siveness (p = 0.0069; Fig. 2D).  
 
 
Figure 2. Kaplan-Meier analysis of distant metastasis-free survival (DMFS) and overall survival (OS) based on HOXB5 expression in the online dataset. Survival was 
compared between the HOXB5-high and -low expression groups. (A) DMFS for all of the breast cancer patients in the dataset. (B) DMFS for ER-positive patients. (C) 
DMFS for the patients with ER-positive, lymph node-negative, histologic grade (HG) I. (D) OS for the patients who received endocrine therapy only.  





HOXB5 promotes breast cancer cell growth 
and invasion in vitro 
To explore the functional relevance of HOXB5 to 
ER-positive breast cancer, we examined the effect of 
HOXB5 knockdown and ectopic expression on tumor 
cell behavior. Lentiviral infection of shRNA constructs 
in ER-positive T47D cells resulted in a reduction of 
HOXB5 expression at the mRNA and protein level 
(Fig. 3A, B). Three stable cell lines (sh_HOXB5#1, -#2, 
and -#3) with low HOXB5 expression exhibited re-
duced cell proliferation and lower levels of anchor-
age-independent growth (Fig. 3C, D).  
For the overexpression studies, the MCF7 cell 
line was chosen as a model system since it expresses 
very low levels of endogenous HOXB5 [10]. Com-
pared to the clonal cells containing empty vector only 
(MCF7:empty vec), the cells with HOXB5 expression 
vector highly expressed HOXB5, which was con-
firmed by PCR (Fig. 4A) and western blotting (Fig. 
4B), as well as by immunocytochemistry (Fig. 5B, D). 
Out of two independent clonal cell lines, 
MCF7:HOXB5 #2 cells had a 5-fold greater HOXB5 
expression than MCF7:HOXB5 #1 cells, based on 
qPCR data, however, these two clonal cells behaved 
similarly. High expression of HOXB5 promoted cell 
proliferation compared with the cells harboring 
empty vector as well as parent MCF7 cells (Fig. 4C). In 
addition, the cells with high HOXB5 expression facil-
itated anchorage-independent cell growth and 
showed significant increases in both number and size 
of colonies in soft agar (Fig. 4D, E). More interestingly, 
the strong ectopic expression of HOXB5 in MCF7 cells 
showed typical features of EMT, with a cellular mor-
phological change from cobblestone-like to a spindle 
and fibroblast-like shape (Fig. 5A, C). In addition, 
E-cadherin expression was weaker and dispersed into 
the cytoplasm in HOXB5-overexpressing MCF7 cells 
(Fig. 5E-F’). Western blotting results confirmed that 
the protein levels of E-cadherin were reduced in 
HOXB5 overexpressing cells (Fig. 5K). Together with 
up-regulated expression of Vimentin at the cell 
membrane borders (Fig. 5G-H’), the β-catenin expres-
sion in the cell membrane was shifted to the cyto-
plasm or in the nucleus, without changes in total 
protein levels (Fig. 5G-J’, K). At the transcriptional 
level, induction of Snail2 (also known as Slug), but not 
Snail1, was prominent in HOXB5 overexpressing cells 
(Fig. 5L). Consistent with these functional changes, 
HOXB5 overexpression increased ability to invade 
through the Matrigel (Fig. 5M). These findings indi-
cate that HOXB5 can induce EMT and positively reg-
ulate tumor cell proliferation and invasion.  
 
 
Figure 3. Effect of HOXB5 knockdown in T47D breast cancer cell lines. (A) Comparison of mRNA expression levels of HOXB5 in stable cell lines (sh_HOXB5 #1, 
-#2, and -#3 vs. sh_NS #1, -#2, and -#3) acquired after knockdown with HOXB5 shRNA (sh_HOXB5) or non-specific (NS) shRNA (sh_NS). The fold change shown 
in the graph was quantitated by realtime PCR. *p < 0.05, **p < 0.01 vs. sh_NS #1. (B) Immunoblot analysis of HOXB5 expression in three independent T47D stable 
cells expressing shRNA against HOXB5 (T47D-sh_HOXB5 #1, -#2, and -#3) and three control cells (T47D-sh_NS #1, -#2, and -#3). (C) Cell proliferation was 
measured by colorimetric MTT assay. ***p < 0.001 vs. sh_NS #2. (D) Soft agar colony formation by T47D-sh_HOXB5 and sh_NS cells. The photographs on the right 
show a representative image of each HOXB5 KD and control group. *p < 0.05, **p < 0.01 vs. sh_NS #2.  






Figure 4. Effect of HOXB5 overexpression in a MCF7 breast cancer cell line. (A) Comparison of mRNA expression levels of HOXB5 in HOXB5 overexpressing cells 
(MCF7:HOXB5 #1 and -#2) with control cells (MCF7:empty vec #1 and parent MCF7). The fold change shown in the graph was quantitated by realtime PCR. (B) 
Immunoblot analysis of HOXB5 expression in two clones with high HOXB5 and control cells (MCF7:empty vec #1 and parent MCF7). Antibody against HA tag was 
used to confirm the protein expression. (C) Effect of HOXB5 overexpression in cell proliferation was measured by colorimetric MTT assay. (D-E) Soft agar colony 
forming assay. The total count number (D) and the average size of colonies (E) are shown in the graph. *p < 0.05, **p < 0.01, ***p < 0.001 vs. MCF7:empty vec #1 for 
all (A) to (E).  
 
Effect of HOXB5 on the expression of breast 
cancer-related genes and tamoxifen resistance 
In breast cancer cells, overexpression of the re-
ceptor tyrosine kinase gene RET, as well as the 
ErbB/HER family members and other growth factor 
receptors, has been linked to the tamoxifen resistance 
and the development of more aggressive, estro-
gen-independent tumors. The results from our in vitro 
models demonstrate that knockdown of HOXB5 led to 
a reduction in transcript levels of RET, ERBB2 and 
EGFR (Fig. 6A). In contrast, a high ectopic expression 
of HOXB5 in MCF7 cells showed an opposite effect on 
the expression of EGFR (Fig. 6B). In both knockdown 
and overexpression systems, ESR1, which encodes 
estrogen receptor 1, had small changes in transcrip-
tional levels (Fig. 6A, B). Interestingly, MTT prolifera-
tion assays revealed that MCF7 cells overexpressing 
HOXB5 were more resistant to tamoxifen (Fig. 6C, D). 
Taken together, these data suggest a possible role of 
HOXB5 on endocrine resistance in breast cancer.  
Discussion 
In this study, we demonstrated that the expres-
sion level of the HOXB5 protein was higher in breast 
cancer tissues compared to normal tissues. In partic-
ular, HOXB5-positive patients showed a higher rate of 
ER-positive tumors. Although more cases are neces-
sary to validate our data, this result suggests that it is 
worth investigating the function of HOXB5 in breast 
cancer biology. Furthermore, survival analysis using 
online resources have shown an association between 
high HOXB5 and poor DMFS in patient groups with 
ER-positive breast cancer, implying a clinical signifi-
cance of HOXB5 in ER-positive breast cancer. To cor-
relate and validate the results of this human study, we 
performed an in vitro assay for HOXB5 in breast can-
cer cell lines. HOXB5 knockdown in T47D led to re-
duced cell proliferation and a lower rate of anchor-
age-independent growth. MCF7 cells overexpressing 
HOXB5 had an opposite effect on cell proliferation as 
well as on tumor cell growth in soft agar. Moreover, 
an ectopic expression of HOXB5 enhanced invasion 
and induced an EMT.  






Figure 5. Morphological changes with EMT features in the cells with high HOXB5 expression. (A-D) Cell morphology detected under bright field microscope (A and 
C) and the immunofluorescence analysis of HOXB5 expression (B and D). (E-J’) E-cadherin (E-F’), Vimentin (G-H’), and β-catenin (I-J’) expression in MCF7:empty vec 
#1 (E, E’, G, G’, I, and I’) and MCF7:HOXB5 #1 (F, F’, H, H’, J, J’) cells. The boxed regions in E, F, G, H, I, and J (200x, Scale bar; 100 μm) were magnified and overlayed 
with a DAPI nuclear counterstain (E’, F’, G’, H’, I’, and J’; 600x, Scale bar; 50 μm). (K) Immunoblot analysis of E-cadherin and β-catenin in two clones with high HOXB5 
(MCF7:HOXB5 #1 and -#2) and control MCF7:empty vec #1 cells. (L) Relative mRNA expression levels of Snail1 and Snail2 in the cells with high HOXB5 
(MCF7:HOXB5 #1 and -#2) and control cells. (M) Matrigel invasion assay with the same cells used for immunofluorescence assay shown in A to J’. The invasive cells 
were stained with DAPI. **p < 0.01 vs. MCF7:empty vec #1 in (L) and (M).  






Figure 6. Effect of HOXB5 on the expression of breast cancer-related genes and tamoxifen resistance. (A) Realtime PCR analysis of RET, ERBB2, EGFR, and ESR1 in 
HOXB5 KD cells (T47D sh_HOXB5 #2 and -#3) and control cells. *p < 0.05, **p < 0.01, ***p < 0.001 vs. sh_NS control. (B) Realtime PCR analysis of ERBB2, EGFR, 
and ESR1 in the cells with high HOXB5 (MCF7:HOXB5 #1 and -#2) and control cells. **p < 0.01, ***p < 0.001 vs. MCF7:empty vec #1. (C-D) Cell proliferation was 
measured by the MTT assay at day 1 (C) and day 2 (D) with treatment of 10 μM and 20 μM tamoxifen in the cells with high HOXB5 (MCF7:HOXB5 #1 and -#2) and 
control cells (parent MCF7 and MCF7: empty vec #1). **p < 0.01, ***p < 0.001 vs. MCF7: empty vec #1. 
 
In order to assess whether the function of 
HOXB5 is specific to ER-positive cells or not, we also 
analyzed the effect of HOXB5 overexpression in sev-
eral different breast cancer cell lines. Similar to its 
effect in ER-positive MCF7 cells, HOXB5 overexpres-
sion promoted cell proliferation in ER-negative 
MDA-MB-231 cells, and moreover, HOXB5 slightly 
induced cell proliferation even in MCF10A normal 
human mammary epithelial cells (Supplementary Fig. 
S1). The proliferative response of mammary epithelial 
cells to HOXB5 does not seem to be unique to 
ER-positive cells. However, the HOXB5-induced EMT 
and invasive potential seem to be phenotypic features 
of MCF7 cells, as EMT-like properties were not 
prominent in T47D cells. No phenotypic changes by 
HOXB5 overexpression in MDA-MB-231 cells were 
detectable, probably due to their intrinsically high 
invasive and aggressive properties with fibroblastic 
morphology. Although the overexpression of HOXB5 
seems to induce EMT and cell proliferation in a cell 
context-dependent manner similar to those previous-
ly reported [22, 23], there is still a possibility that 
HOXB5 plays a role as a modulator of EMT predom-
inantly in ER-positive breast cancer cells because 
Snail2, an essential mediator of Twist1-induced EMT, 
was induced by HOXB5 overexpression in 
ER-positive MCF7 and T47D cells, but was not signif-
icantly induced in ER-negative MDA-MB-231 cells 
(Supplementary Fig. S2). Further analysis in 
ER-negative breast cells will be necessary to define the 
role of HOXB5 in ER-negative breast tumors. 
One of the interesting findings in this study was 
the dysregulation of RET, ERBB2/HER2, and EGFR as 
a consequence of HOXB5 silencing or overexpression. 
Trastuzumab, an inhibitor of ERBB2, is very well 
known as a therapeutic agent for HER2-positive 
breast cancer. An agent targeting EGFR is also cur-
rently under development for triple negative breast 





cancer [24]. Taken together with our HOXB5 knock-
down experiments, in which cell proliferation and 
colony formation were suppressed, HOXB5 is ex-
pected to be a putative therapeutic target for breast 
cancer. In addition, cross-talk between ER signaling 
and the ERBB2 or EGFR pathway is a well-known 
mechanism of endocrine therapy resistance [25]. RET 
has also been reported to be associated with endocrine 
resistance [26]. Although there has been no strong 
evidence to link between HOXB5 and the key genes 
involved in endocrine resistance, we showed here a 
drastic up-regulation of EGFR transcripts when the 
cells over-expressed the HOXB5, which may contrib-
ute to endocrine-resistant phenotype. Together with 
the current in vitro studies showing tamoxifen re-
sistance in HOXB5 overexpressing MCF7 cells, the 
survival analysis showed a correlation between high 
HOXB5 expression and a poor response to endocrine 
therapy. Since it strongly suggests a possible role of 
HOXB5 in endocrine therapy resistance, it is worth-
while to investigate further whether HOXB5 could be 
a therapeutic target to overcome this resistance. 
 Several HOXB cluster genes, such as HOXB2, 
HOXB7, HOXB9, and HOX13, have been reported to 
play a role in breast cancer. HOXB2 has been pro-
posed to be a negative growth regulator, whereas 
HOXB7, HOXB9, and HOXB13 confer more aggres-
sive phenotypes and are responsible for poorer 
prognoses [8, 9, 11]. HOXB7 and HOXB9 promoted 
EMT phenotypes [11, 21], and HOXB7 and HOXB13 
have recently been identified as mediating tamoxifen 
resistance [8, 9]. Recent advances in elucidating dif-
ferent functions of HOX genes shed valuable light on 
the molecular links between the dysregulation of each 
HOX gene and the altered cellular functions that con-
tribute to the development of cancer. Findings such as 
those in one study reporting the cluster-based regula-
tion of HOXB genes in Barrett’s esophagus (BE) [27] 
might open a way to target several HOX genes to-
gether for cancer therapy, for example, by controlling 
common enhancers or epigenetic factors affecting 
cluster genes.  
In summary, our work provides new insight into 
the physiological significance and potential clinical 
applications of HOXB5, which modulates cell prolif-
eration and tumor progression in ER-positive breast 
cancer. Because a single gene may have different 
function depending on the tissue or cell type, further 
studies to identify the molecular basis of HOXB5 reg-
ulation and its impacts on particular types of breast 
cancer are needed to validate HOXB5 as a potential 
therapeutic target and biomarker in breast cancer.  
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